Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AFYX-006 + AFYX-007
- Development stage
- Unknown
- Lead developer
- AFYX Therapeutics
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
AFYX-006 + AFYX-007 is a combination chemotherapy product being developed by AFYX Therapeutics for the treatment of oral potentially malignant lesions (OPML) and head and neck cancer. The product utilizes the proprietary Rivelin patch technology, which is a flexible, biodegradable, mucoadhesive patch designed to deliver chemotherapeutic agents directly to premalignant or malignant lesions in the oral cavity. This localized delivery method is intended to maximize therapeutic efficacy at the site of the lesion while minimizing systemic exposure and associated side effects. AFYX-007 specifically is currently in Phase 1 clinical development for head and neck cancer.
Beyond the preview
Go deeper on AFYX-006 + AFYX-007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AFYX-006 + AFYX-007.